Dysfunction of neuronal communication and up-regulation of certain types of brain inflammation contribute to disease susceptibility and are common denominators for disease progression in diverse neurodegenerative diseases. There are no existing drugs or drugs in current clinical trials that adequately block these disease progression mechanisms. MW150 is a novel, custom designed, small molecule candidate that addresses this gap in disease progression intervention. MW150's exceptional qualifications in FDA recommended preclinical safety studies and in preclinical animal model efficacy tests make it relevant to disease progression in multiple areas of unmet need. MW150 is efficacious in both preventive and disease stage therapeutic treatment paradigms. It improves outcomes in distinct models of Alzheimer's disease and other dementias for which there are no current approved therapies. Further, MW150 targets distinct pathways from current AD or dementia drugs or drugs in late stage clinical trials. Overall, the proposed investigations raise the possibility of a new therapeutic intervention that has potential as a mono-therapy or part of a multiple drug armamentarium. All the data support to move now into the first testing of MW150 in patients. ADDF support of phase 1 studies will make MW150 the first drug in this class to be tested in humans. The resultant phase 1 clinical outcomes will provide a firm and necessary foundation for future planned and 2a clinical trials, in particular because in parallel long term safety studies will be completed to form the regulatory basis to move into clinical trials in AD patients, with adequate treatment time ( 6 to 12 months) . The molecular and pharmacological aspects of MW150 make it a unique choice for these future clinical investigations.